Author:
Anderssona M.,Awadab A.,Barrett-Leec P.,Ellisd P.,Hupperetse P.,Jackischf C.,Kubistag E.,Lückh H.-J.,Monnerati C.,Nitzj U.,Untchl M.
Reference33 articles.
1. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule;Baselga;J Clin Oncol,2005
2. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer;Pegram;J Clin Oncol,2007
3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001
4. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005
5. Superior long- term survival benefit of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2- positive metastatic breast cancer: patients surviving more than four years in the M77001 study;Marty;San Antonio Breast Cancer Symposium,2006
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献